Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> HIV-1 protease-IN-7 [2916441-36-4]

HIV-1 protease-IN-7 [2916441-36-4]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-151250

Size : Getquote

Marke : MedChemExpress

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790

HIV-1 protease-IN-7 (compound 16) is an orally active HIV-1 protease inhibitor (IC50=3.52 nM, EC50=37 nM).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Kundenspezifische Peptidsynthese

HIV-1 protease-IN-7 Chemische Struktur

HIV-1 protease-IN-7 Chemische Struktur

CAS. Nr. : 2916441-36-4

This product is a controlled substance and not for sale in your territory.

Beschreibung

HIV-1 protease-IN-7 (compound 16) is an orally active HIV-1 protease inhibitor (IC50=3.52 nM, EC50=37 nM)[1].

IC50 & Target

HIV-1 protease[1].
In Vivo

HIV-1 protease-IN-7 (2.57 mg/kg; p.o.; single) exhibits good plasma total clearance and oral bioavailability[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (8-week-old)[1].
Dosage: 2.57 mg/kg (2 μM/kg)
Administration: Oral administration; single.
Result: 1.19 Pharmacokinetic Parameters of HIV-1 protease-IN-7 in male Sprague-Dawley rats[1].
metabolic stability rat/human (%) CLtot (mL/min/kg) Vdss (L/kg) t1/2 (h) F (%) serum fu(%)
PO (2.57 mg/kg) 63/23 8.2 1.9 3.9 3.3 0.1
Molekulargewicht

1285.68

Formel

C68H104N10O12S
CAS. Nr.

2916441-36-4
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise

  • [1]. Kusumoto Y, et al. Highly Potent and Oral Macrocyclic Peptides as a HIV-1 Protease Inhibitor: mRNA Display-Derived Hit-to-Lead Optimization. ACS Medicinal Chemistry Letters, 2022.

  • [1]. Kusumoto Y, et al. Highly Potent and Oral Macrocyclic Peptides as a HIV-1 Protease Inhibitor: mRNA Display-Derived Hit-to-Lead Optimization. ACS Medicinal Chemistry Letters, 2022.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

HIV-1 protease-IN-7 Related Classifications

  • Infection
  • Anti-infection Metabolic Enzyme/Protease
  • HIV Protease

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HIV-1 protease-IN-72916441-36-4HIV ProteaseHIV-1Inhibitorinhibitorinhibit